We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Rapid Test Developed for Sickle Cell Anemia

By LabMedica International staff writers
Posted on 20 Sep 2011
A new blood test is being developed, which, for the first time, could help identify babies at risk of a severe form of sickle cell disease. More...


Babies with sickle cell disease have abnormal red blood cells and the test works by detecting these cells, which burst under certain conditions allowing an immediate diagnosis and more intensive treatment to be given.

Scientists from British Universities are collaborating to replace the diagnostic tests for sickle cell disease, which are complicated, requiring skilled technicians, and sophisticated and expensive equipment. Those tests are time consuming and are often not useful in an emergency situation. The newer test involves mixing a blood sample with a special sugar solution in low oxygen. Red blood cells from a baby who has sickle cell disease burst in the liquid, which becomes pink. Cells from a healthy baby do not burst, and the liquid stays clear.

None of the existing tests can predict how severe a baby's illness is likely to be. Babies who are at risk of the most severe symptoms, who might benefit greatly from early and intensive treatment, cannot be easily identified before they become poorly. Children with sickle cell disease face a lifetime of ill health. They have attacks of intense pain called crises, which can last several days. They are prone to infections and anemia, which can be life threatening. They are at risk of a variety of complications, including organ failure, strokes, and leg ulcers, and they have a shortened life expectancy.

An estimated 20 million people are affected worldwide and over 12,000 people in the UK have sickle cell disease, the country's most common severe genetic disorder. Symptoms usually start early in babies who are just six to nine months old. John Gibson, PhD, from the University of Cambridge (UK) is the project leader and working with colleagues at King's College Hospital, (London, UK) have enrolled 120 children and adults with sickle cell disease who will donate blood samples for testing. He said, "The aim of this project is to perfect the diagnostic test, so it can be used routinely at the bedside".

Related Links:
University of Cambridge
King's College Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NeoGenomics selected Indica Labs’ HALO AP platform to eable its digital pathology operations through a scalable, cloud-based framework (Photo courtesy of Indica Labs)

Expanded Partnership Scales AI-Powered Digital Pathology for Oncology

Oncology diagnostics rely on pathology and biomarker information to guide personalized treatment. As computational pathology and artificial intelligence (AI) expand insights from tissue analysis, laboratories... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.